| Předmět: |
|
| Zdroj: |
Immunotherapy Weekly; 12/17/2024, p683-683, 1p |
| Abstrakt: |
A study conducted at Ankara City Hospital compared the effectiveness and safety of FOLFIRI and bevacizumab versus FOLFIRI and aflibercept in patients with RAS-mutant metastatic colon cancer. The study included 243 patients from 15 different centers in Turkey, with results showing better overall survival and progression-free survival in patients receiving bevacizumab with FOLFIRI. Additionally, the side effect profile was more tolerable in the bevacizumab arm. This research provides valuable insights for the treatment of metastatic colon cancer in patients who have progressed after first-line chemotherapy. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
